10x Genomics (TXG) has drawn investor attention after recent share price gains over the past month and past 3 months. The stock closed at $64.72 on 26 August 2026, with recent returns significantly higher than its 1-year figure.

For you as an investor, the recent momentum in 10x Genomics is hard to ignore. The 30 day share price return is 39.87% and the 90 day share price return is 153.70%, while the 1 year total shareholder return of 361.30% contrasts with a 5 year total shareholder return that is still down 63.21%.

Scan for other stocks showing similar momentum to 10x Genomics by reviewing the hand picked 18 high quality undiscovered gems, which also pair strong recent moves with underlying fundamentals.

10x Genomics now pairs a growing global footprint and rising annual revenue with a share price that has moved sharply higher in a short period. Does the current valuation still reflect the business, or has enthusiasm run ahead of itself?

Most Popular Narrative: 30.6% Overvalued

The most followed narrative pegs 10x Genomics fair value at $49.54 compared with the latest close at $64.72, which points to stretched expectations based on those assumptions.

Recent and upcoming product launches including Flex v2 (targeting higher throughput, lower costs, and AI integration), Visium HD extensions, and Xenium RNA plus protein are expanding the range of applications and reinforcing 10x''s leadership in advanced genomics tools, expected to drive both top-line growth and sustain premium pricing over time.

Want to see what kind of revenue curve and future margins have to line up to support that fair value for 10x Genomics? The narrative leans on rising consumables mix, higher throughput platforms, and a richer earnings profile several years out. The specific assumptions behind those moves might surprise you.

Result: Fair Value of $49.54 (OVERVALUED)

However, investors in 10x Genomics still need to weigh softer research budgets and discounting on instruments, which could pressure margins and delay any earnings recovery.

Next Steps

Given the mixed sentiment around 10x Genomics, you may want to review the underlying data yourself and decide how comfortable you are with the current setup. To see both the concerns investors are flagging and the potential upside others are focused on, review the 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond 10x Genomics?

If 10x Genomics has caught your attention, do not stop there. Broaden your watchlist with other focused ideas that could better fit your risk and income goals.

• Target potential mispricing by scanning companies that combine quality with attractive valuations through the 49 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies with higher yields and resilience using the 12 dividend fortresses.
• Reduce surprises in your portfolio by focusing on stocks with steadier profiles through the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.